Where to Get TMS Therapy in Colorado Springs Starts with Serenity Mental Health Centers

Serenity clinics offer accessible TMS treatment for mental health. COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Serenity Mental Health Centers, a leader in innovative psychiatric care and one of the fastest-growing mental health providers in the nation, is setting the standard for TMS therapy in Colorado Springs. Serenity’s board-certified psychiatrists and psychiatric mental health nurse practitioners provide full-spectrum mental … [Read more…]

Serenity Mental Health Centers Expands Access in Colorado Springs with FDA-cleared Accelerated Deep TMS Protocol

Patients nationwide can access faster, convenient TMS treatment. COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Serenity Mental Health Centers, a leader in innovative psychiatric care and one of the fastest-growing mental health providers in the nation, today announced that its patients now have immediate access to the FDA-cleared accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol from BrainsWay for … [Read more…]

Appointment of Yves Decadt as Member of Poxel’s Board of Directors

LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors. Following the governance changes implemented … [Read more…]

TruBridge Announces Third Quarter 2025 Conference Call to Be Held Friday, November 7, 2025

MOBILE, Ala.–(BUSINESS WIRE)–TruBridge, Inc. (NASDAQ: TBRG), a leading provider of revenue cycle management and healthcare technology solutions for rural and community healthcare organizations, today announced that it will release its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the market closes. The Company will host a conference … [Read more…]

SharkNinja Turns Viral ‘Chicken Smoothie’ Moment from Netflix’s Love Is Blind into Protein-Packed Ice Cream Collaboration

Ninja Swirl™ is featured in the Season 9 reunion episode as SharkNinja showcases its fast, culture-driven marketing approach NEEDHAM, Mass.–(BUSINESS WIRE)–SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today announced a partnership with Netflix’s Love Is Blind. The partnership is a fun play on one of the season’s most viral moments featuring … [Read more…]

Calluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a DAMP protein implicated in severe, life-threatening fibrotic diseases CAL101 being investigated in Phase 2 IPF Study; enrollment ongoing at sites in the USA, UK, EU, Turkey and South Korea OSLO, Norway & BOSTON–(BUSINESS WIRE)–Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat … [Read more…]

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $18.25 per share. Gross … [Read more…]

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or metastatic HER2 overexpressing and PD-L1 TPS <50% non-squamous non-small cell lung cancer (NSCLC). ENHERTU is … [Read more…]

QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA Workflow on EZ2 Connect Fx delivers high-quality DNA in under 2.5 hours, minimizing hands-on time and variability with current manual process QIAGEN to showcase new kit and forensics portfolio at upcoming ISHI 2025 meeting GERMANTOWN, … [Read more…]

Paynela Expands its Operations to Kalispell, Montana, Marking a New Era of Growth and Innovation

KALISPELL, Mont.–(BUSINESS WIRE)–Paynela, LLC the healthcare fintech company redefining how patients pay for and access prescription medications, announced today that it has officially expanded its operations to Kalispell, Montana. The move underscores Paynela’s continued growth and its mission to make healthcare payments more transparent, efficient, and patient-centered. The company’s new location in Kalispell positions it … [Read more…]